Sophia Genetics Sa ( (SOPH) ) has released its Q2 earnings. Here is a breakdown of the information Sophia Genetics Sa presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
SOPHiA GENETICS SA, a cloud-native software company specializing in data-driven medicine, focuses on expanding access to genomic and multimodal data analysis through its SOPHiA DDM™ platform, serving a global network of healthcare institutions.
In its second quarter of 2025, SOPHiA GENETICS reported a 16% year-over-year increase in revenue, reaching $18.3 million. The company highlighted significant business wins, including a major partnership with AstraZeneca, and continued expansion of its customer base and product offerings.
Key financial metrics for the quarter include a gross margin of 67% on a reported basis, with an adjusted gross margin of 74.4%. Despite an increase in net loss by 48% to $22.4 million, the company improved its cash burn by 35% to $8.7 million. SOPHiA GENETICS also signed 35 new core genomics customers and expanded its partnership with Dasa, enhancing its market presence.
The company continues to drive growth through strategic partnerships and new applications, such as MSK-ACCESS® powered by SOPHiA DDM™, which saw increased adoption. SOPHiA GENETICS remains committed to its financial guidance for 2025, projecting revenue between $72 million and $76 million and an adjusted EBITDA loss between $35 million and $39 million.
Looking ahead, SOPHiA GENETICS aims to achieve profitable growth, with expectations to approach adjusted EBITDA breakeven by the end of 2026 and move to positive adjusted EBITDA in the second half of 2027, reflecting a strong commitment to operational excellence and strategic expansion.